Glenmark Pharmaceuticals S.a.

Ashok Bhausaheb Kadam

Neelima Khairatkar-Joshi

Abraham Thomas

Sachin Sundarlal Chaudhari

Sachin Vasantrao Dhone

Suresh Mahadev Kadam

Sukeerthi Kumar

Indranil Mukhopadhyay

Vishal Govindrao Deshmukh

Nisha Parag Patil

Rajendra Prakash Chikhale

Vidya Ganapati Kattige

Daisy Manish Shah

Malini Bajpai

V S Prasada Rao Lingam

Shantaram Kashinath Phatangare

Bharat G Adik

Thomas Abraham

Deepak Vitthal Ukride

Neelima Khairatkar-joshi

The present disclosure is directed to compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein Ring A, Ring B, R, R, R, n, and p are as defined herein, which are active as modulators of retinoid-related orphan receptor gamma t (ROR&#x3b3;t). These compounds prevent, inhibit, or suppress the action of ROR&#x3b3;t and are therefore useful in the treatment of ROR&#x3b3;t mediated diseases, disorders, syndromes or conditions such as, e.g., pain, inflammation, COPD, asthma, rheumatoid arthritis, colitis, multiple sclerosis, psoriasis, neurodegenerative diseases and cancer. 

Aryl and heteroaryl ether compounds as ROR gamma modulators

The invention described herein relates to novel fused pyrimidinediones derivatives of formula (I) which are TRPA (Transient Receptor Potential subfamily A) modulators. In particular, compounds described herein are useful for treating or preventing diseases, conditions and/or disorders modulated by TRPA1 (Transient Receptor Potential subfamily A, member 1). This invention also provides processes for preparing compounds described herein, intermediates used in their synthesis, pharmaceutical compositions thereof, and methods for treating or preventing diseases, conditions and/or disorders modulated by TRPA1. 

Fused pyrimidine-dione derivatives as TRPA1 modulators

The present invention provides transient receptor potential vanilloid (TRPV) modulators of formula (I). In particular, compounds described herein are useful for treating or preventing diseases, conditions and/or disorders modulated by TRPV3. Also provided herein are processes for preparing compounds described herein, intermediates used in their synthesis, pharmaceutical compositions thereof, and methods for treating or preventing diseases, conditions and/or disorders modulated by TRPV3. 

Fused imidazole carboxamides as TRPV3 modulators

The present invention relates to novel processes for preparing DPP-IV inhibitors having the structure of formula I, and pharmaceutically acceptable salt thereof, which are useful for treatment of Type 2 diabetes.

Processes for the preparation of DPP IV inhibitors

Growing community of inventors

Navi Mumbai, India

Ashok Bhausaheb Kadam